Ex-Genzyme ops chief joins board at bio start-up

Manufacturing ops veteran Scott Canute has joined the board at biotech start-up Oncobiologics. Canute, recently president for global manufacturing and corporate ops at Genzyme, was brought in to remediate operations at the biotech's Boston-area plant.

Canute is also former president for global manufacturing ops at Eli Lilly ($LLY), according to an announcement. He brings 30 years of biopharma production expertise to the startup, which is holding a grand opening event at its Cranbury, NJ headquarters this Friday, October 14, 2011.

In early 2010, Canute joined Genzyme as part of a high-level operations restructuring at the facility where a virus contaminated a bioreactor, leading to a plant shutdown for decontamination.  Canute was teamed with Ron Branning, former head of quality and compliance at Gilead Sciences ($GILD), Sandra Poole as senior VP and site leader, and consultancy Quantic Group for manufacturing operations. Remediation work is still underway.

Canute left Genzyme in July, says Boston.com, after it became a unit of Sanofi ($SNY) and the French drug giant transferred oversight of all Genzyme manufacturing ops to Bill Aitchison, former manufacturing head at Sanofi Pasteur vaccines.

- here's the release
- see the story

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.